Ascites-Derived Organoids for Prediction of Treatment Response and Clinical Management in Ovarian Cancer: A Case Report
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
High grade serous ovarian cancer patients initially respond to platinum-based chemotherapy but usually relapse within two years and ultimately develop therapy resistance. Management of response and effective clinical decisions are currently based on nonspecific biomarkers and limited imaging techniques, illustrating the clear clinical need for reliable predictors of response.
Method
In this Case Report, we evaluated the performance of patient-derived organoids generated from ascitic fluid at diagnosis and pharmacologically tested in parallel to the patient’s clinical course, in the prediction of treatment response, and to guide clinical decision-making in a patient-specific manner.
Results
Ascites-derived organoids reliably recapitulated the histological and molecular features of a paradigmatic HGSOC patient with an apparent clinical response to chemotherapy, and predicted chemoresistance months before laparoscopy confirmed persistent inoperable disease with poor pathological response. Drug screening identified alternative therapeutic options, while multi-omics analysis provided additional insights into the tumor-specific biological features that may support personalized treatment strategies in ovarian cancer.
Conclusion
This work illustrates how patient-derived organoids generated from a minimally invasive liquid biopsy can complement conventional clinical, radiological, and molecular assessments. Functional pharmacology combined with genomic and transcriptomic profiling may anticipate treatment response and contribute to more personalized management in ovarian cancer.
